Gene test may personalize heart drug dosing

NCT ID NCT07439952

First seen Mar 19, 2026 · Last updated Apr 29, 2026 · Updated 5 times

Summary

This study looks at how a person's genes influence their response to the heart drug mavacamten, used for obstructive hypertrophic cardiomyopathy. Researchers will collect DNA samples from 300 patients to see why some respond better than others. The goal is to make treatment safer and more effective by tailoring doses based on genetic type.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for OBSTRUCTIVE HYPERTROPHIC CARDIOMYOPATHY (OHCM) are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • APHP, Ambroise Paré

    Boulogne-Billancourt, 92100, France

    Contact

    Contact Email: •••••@•••••

  • APHP, Bicêtre hospital

    Le Kremlin-Bicêtre, France

    Contact Email: •••••@•••••

    Contact

  • APHP, La Pitié Salpetriere hospital

    Paris, 75013, France

    Contact Email: •••••@•••••

    Contact

Conditions

Explore the condition pages connected to this study.